U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07358806) titled 'Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors' on Dec. 07, 2025.
Brief Summary: This is a Phase 1 study intended to determine the MTD of OCT-598 following multiple-dose therapy and to establish the RP2D for OCT-598 as a single agent, by assessing its safety and tolerability as monotherapy and in combination with standard-of-care treatments in patients with advanced solid tumors.
Study Start Date: Dec. 18, 2025
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Breast Cancer
Head and Neck Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Gastric/Gastroesophageal Junction Cancer
Intervention:
DRUG: ...